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Chorionic Villus Sampling and Amniocentesis:
Recommendations for Prenatal Counseling
Summary
Chorionic villus sampling (CVS) and amniocentesis are prenatal diagnostic
procedures that are performed to detect fetal abnormalities. In 1991, concerns
about the relative safety of these procedures arose after reports were published
that described a possible association between CVS and birth defects in infants.
Subsequent studies support the hypothesis that CVS can cause transverse limb
deficiencies. Following CVS, rates of these defects, estimated to be 0.03%–0.10%
(1/3,000–1/1,000), generally have been increased over background rates. Rates
and severity of limb deficiencies are associated with the timing of CVS; most of
the birth defects reported after procedures that were performed at ≥70 days’
gestation were limited to the fingers or toes.
The risk for either digital or limb deficiency after CVS is only one of several
important factors that must be considered in making complex and personal de-
cisions about prenatal testing. For example, CVS is generally done earlier in
pregnancy than amniocentesis and is particularly advantageous for detecting
certain genetic conditions. Another important factor is the risk for miscarriage,
which has been attributed to 0.5%–1.0% of CVS procedures and 0.25%–0.50% of
amniocentesis procedures. Prospective parents considering the use of either
CVS or amniocentesis should be counseled about the benefits and risks of these
procedures. The counselor should also discuss both the mother’s and father’s
risk(s) for transmitting genetic abnormalities to the fetus.
INTRODUCTION
Chorionic villus sampling (CVS) and amniocentesis are prenatal diagnostic proce-
dures used to detect certain fetal genetic abnormalities. Both procedures increase the
risk for miscarriage (1 ). In addition, concern has been increasing among health-care
providers and public health officials about the potential occurrence of birth defects
resulting from CVS (2 ).
This report describes CVS and amniocentesis, provides information on indications
for their use, reviews studies about the safety of the procedures, compares the bene-
fits and risks of the two procedures (focusing particularly on the risk for limb
deficiency after CVS), and provides recommendations for counseling about these
issues.  A public meeting was convened on March 11, 1994, to discuss the results of
studies of CVS-associated limb deficiencies and preliminary counseling recommenda-
tions that had been drafted at CDC (3 ). Participants included geneticists, obstetricians,
pediatricians, epidemiologists, teratologists, dysmorphologists, and genetic counsel-
ors who had a particular interest in CVS studies or who represented professional
organizations and government agencies. Participants provided diverse opinions about
recommendations for counseling both at the meeting and in subsequent written cor-
respondence; input from participants has been incorporated into this document.
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USE OF CVS AND AMNIOCENTESIS
CVS utilizes either a catheter or needle to biopsy placental cells that are derived
from the same fertilized egg as the fetus. During amniocentesis, a small sample of the
fluid that surrounds the fetus is removed. This fluid contains cells that are shed pri-
marily from the fetal skin, bladder, gastrointestinal tract, and amnion. Typically, CVS is
done at 10–12 weeks’ gestation, and amniocentesis is done at 15–18 weeks’ gestation.
In the United States, the current standard of care in obstetrical practice is to offer
either CVS or amniocentesis to women who will be ≥35 years of age when they give
birth, because these women are at increased risk for giving birth to infants with Down
syndrome and certain other types of aneuploidy. Karyotyping of cells obtained by
either amniocentesis or CVS is the standard and definitive means of diagnosing
aneuploidy in fetuses. The risk that a woman will give  birth to an infant with Down
syndrome increases with age. For example, for women 35 years of age, the risk is 1
per 385 births (0.3%), whereas for women 45 years of age, the risk is 1 per 30 births
(3%) (1 ). The background risk for major birth defects (with or without chromosomal
abnormalities) for women of all ages is approximately 3%.
Before widespread use of amniocentesis, several controlled studies were con-
ducted to evaluate the safety of the procedure. The major finding from these studies
was that amniocentesis increases the rate for miscarriage (i.e., spontaneous abor-
tions) by approximately 0.5%. Subsequent to these studies, amniocentesis became an
accepted standard of care in the 1970s. In 1990, more than 200,000 amniocentesis
procedures were performed in the United States (4 ).
In the 1960s and 1970s, exploratory studies were conducted revealing that the pla-
centa (i.e., chorionic villi) could be biopsied through a catheter and that sufficient
placental cells could be obtained to permit certain genetic analyses earlier in preg-
nancy than through amniocentesis. In the United States, this procedure was initially
evaluated in a controlled trial designed to determine the miscarriage rate (5 ). The
difference in fetal-loss rate was estimated to be 0.8% higher after CVS compared with
amniocentesis, although this difference was not statistically significant. Because that
study was designed to determine miscarriage rates, it had limited statistical power to
detect small increases in risks for individual birth defects.
CVS had become widely used worldwide by the early 1980s. The World Health Or-
ganization (WHO) sponsors an International Registry of CVS procedures; data in the
International Registry probably represent less than half of all procedures performed
worldwide (6).  More than 80,000 procedures were reported to the International Regis-
try from 1983–1992 (6); approximately 200,000 procedures were registered from
1983–1995 (L. Jackson, personal communication). CVS is performed in hospitals, out-
patient clinics, selected obstetricians’ offices, and university settings; these facilities
are often collectively referred to as prenatal diagnostic centers. Some investigators
have reported that the availability of CVS increased the overall utilization of prenatal
diagnostic procedures among women ≥35 years of age, suggesting that access to
first-trimester testing may make prenatal chromosome analysis appealing to a larger
number of women (7 ). Another group of obstetricians did not see an increase in over-
all utilization when CVS was introduced (8 ). The increase in CVS procedures was
offset by a decrease in amniocentesis, suggesting that the effect of CVS availability on
the utilization of prenatal diagnostic testing depends on local factors. In the United
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States, an estimated 40% of pregnant women ≥35 years of age underwent either am-
niocentesis or CVS in 1990 (9 ).
Although maternal age-related risk for fetal aneuploidy is the usual indication for
CVS or amniocentesis, prospective mothers or fathers of any age might desire fetal
testing when they are at risk for passing on certain mendelian (single-gene) condi-
tions. In a randomized trial conducted in the United States, 19% of women who
underwent CVS were <35 years of age (10).  DNA-based diagnoses of mendelian con-
ditions, such as cystic fibrosis, hemophilia, muscular dystrophy, and
hemoglobinopathies, can be made by direct analysis of uncultured chorionic villus
cells (a more efficient method than culturing amniocytes) (11 ). However, amniocente-
sis is particularly useful to prospective parents who have a family history of neural
tube defects, because alphafetoprotein (AFP) testing can be done on amniotic fluid but
cannot be done on CVS specimens.
When testing for chromosomal abnormalities resulting from advanced maternal
age, CVS may be more acceptable than amniocentesis to some women because of the
psychological and medical advantages provided by CVS through earlier diagnosis of
abnormalities. Fetal movement is usually felt and uterine growth is visible at 17–19
weeks’ gestation, the time when abnormalities are detected by amniocentesis; thus,
deciding what action to take if an abnormality is detected at this time may be more
difficult psychologically (12 ). Using CVS to diagnose chromosomal abnormalities
during the first trimester allows a prospective parent to make this decision earlier than
will amniocentesis.
Maternal morbidity and mortality associated with induced abortion increase signifi-
cantly with increasing gestational age; thus, the timing of diagnosis of chromosomal
abnormalities is important. Results of studies of abortion complications conducted by
CDC from 1970 through 1978 indicated that the risk for major abortion complications
(e.g., prolonged fever, hemorrhage necessitating blood transfusion, and injury to pel-
vic organs) increases with advancing gestational age. For example, from 1971 through
1974, the major complication rate was 0.8% at 11–12 weeks’ gestation, compared with
2.2% at 17–20 weeks’ gestation (13 ). However, the risk for developing major complica-
tions from abortion at any gestational age decreased during the 1970s. More
contemporary national morbidity data based on current abortion practices are not yet
available. CDC surveillance data also indicate an increase in the risk for maternal death
with increasing gestation. From 1972 through 1987, the risk for abortion-related death
was 1.1 deaths per 100,000 abortions performed at 11–12 weeks’ gestation compared
with 6.9 deaths per 100,000 abortions for procedures performed at 16–20 weeks’ ges-
tation (14 ). The lower risk associated with first-trimester abortions may be an
important factor for prospective parents who are deciding between CVS and amnio-
centesis.
Amniocentesis is usually performed at 15–18 weeks’ gestation, but more amnio-
centesis procedures are now being performed at 11–14 weeks’ gestation. “Early”
amniocentesis (defined as <15 weeks’ gestation) remains investigational, because the
safety of the procedure is currently being evaluated with controlled trials (15 ).
Risk estimates for miscarriage caused by either CVS or midtrimester amniocentesis
have been adjusted to account for spontaneous fetal losses that occur early in preg-
nancy and are not procedure-related. Although one randomized trial indicated that the
amniocentesis-related miscarriage rate may be as high as 1%, counselors usually cite
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risks for miscarriage from other amniocentesis studies ranging from 0.25%–0.50%
(1/400–1/200) (1,15 ). Rates of miscarriage after CVS vary widely by the center at which
CVS was performed (16 ). Adjusting for confounding factors such as gestational age,
the CVS-related miscarriage rate is approximately 0.5%–1.0% (1/200–1/100) (1 ).
Although uterine infection (i.e., chorioamnionitis) is one possible reason for mis-
carriage after either CVS or amniocentesis, infection has occurred rarely after either
procedure. In one study, no episodes of septic shock were reported after 4,200 CVS
procedures, although less severe infections may have been associated with 12 of the
89 observed fetal losses (5 ). Overall infection rates have been <0.1% after either CVS
or amniocentesis (15 ).
Cytogenetically ambiguous results caused by factors such as maternal cell con-
tamination or culture-related mosaicism are reported more often after CVS than after
amniocentesis (2 ). In these instances, follow-up amniocentesis might be required to
clarify results, increasing both the total cost of testing and the risk for miscarriage.
However, ambiguous CVS results also may indicate a condition (e.g., confined placen-
tal mosaicism) that has been associated with adverse outcomes for the fetus (11 ).
Thus, in these situations, CVS may be more informative than amniocentesis alone.
LIMB DEFICIENCIES AMONG INFANTS WHOSE MOTHERS
UNDERWENT CVS
Certain congenital defects of the extremities, known as limb deficiencies or limb-
reduction defects, have been reported among infants whose mothers underwent CVS.
This section addresses 1) the expected frequency and classification of these birth de-
fects, 2) the physical features of reported infants in relation to the timing of associated
CVS procedures, and 3) cohort and case-control studies that have been done to sys-
tematically examine whether CVS increases the risk for limb deficiencies.
Population-Based Rates and Classification of Limb Deficiencies
Population-based studies indicate that the risk for all limb deficiencies is from 5–6
per 10,000 live births (17 ). Limb deficiencies usually are classified into distinct
anatomic and pathogenetic categories. The most common subtypes are transverse
terminal defects, which involve absence of distal structures with intact proximal seg-
ments, with the axis of deficiency perpendicular to the extremity. Approximately 50%
of all limb deficiencies are transverse, and 50% of those defects are digital, involving
the absence of parts of one or more fingers or toes. Transverse deficiencies occur as
either isolated defects or with other major defects. The rare combination of transverse
limb deficiencies with either absence or hypoplasia of the tongue and lower jaw—usu-
ally referred to as oromandibular-limb hypogenesis or hypoglossia/hypodactyly
—occurs at a rate of approximately 1 per 200,000 births. Although the cause of many
isolated limb deficiencies and multiple anomalies that include transverse deficiencies
is unknown, researchers have hypothesized that these deficiencies are caused by vas-
cular disruption either during the formation of embryonic limbs or in already-formed
fetal limbs (17,18 ).
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Limb Deficiencies Reported in Infants Exposed to CVS
Reports of clusters of infants born with limb deficiencies after CVS were first pub-
lished in 1991 (19 ). Three studies illustrate the spectrum of CVS-associated defects
(19–21 ). Data from these studies suggest that the severity of the outcome is associ-
ated with the specific time of CVS exposure. Exposure at ≥70 days’ gestation has been
associated with more limited defects, isolated to the distal extremities, whereas ear-
lier exposures have been associated with more proximal limb deficiencies and
orofacial defects. For example, in a study involving 14 infants exposed to CVS at 63–79
days’ gestation and examined by a single pediatrician, 13 had isolated transverse digi-
tal deficiencies (20 ). In another study in Oxford of five infants exposed to CVS at 56–66
days’ gestation, four had transverse deficiencies with oromandibular hypogenesis
(19 ). In a review of published worldwide data, associated defects of the tongue or
lower jaw were reported for 19 of 75 cases of CVS-associated limb deficiencies (21 ).
Of those 19 infants with oromandibular-limb hypogenesis, 17 were exposed to CVS
before 68 days’ gestation. In this review, 74% of infants exposed to CVS at ≥70 days’
gestation had digital deficiencies without proximal involvement.
Cohorts of CVS-Exposed Pregnancies
Cohort studies usually measure rates of a specified outcome in an exposed group
compared with an unexposed group. Ideally, both groups should be selected ran-
domly from the same study population. The three largest collaborative trials of CVS in
Europe, Canada, and the United States were designed originally in this way; however,
in these studies, the outcome of interest was fetal death. The report of the first U.S.
collaborative trial included no mention of any structural defects; such outcomes were
reported later (5 ).
After the initial case reports in 1991, neonatal outcomes from the collaborative tri-
als were analyzed more intensively (22 ). However, rather than comparing rates for
limb defects in the CVS-exposed cohorts with those of amniocentesis-exposed co-
horts from the same study population, the rates in the CVS groups were compared
with population-based rates. Consequently, these comparisons must be interpreted
with caution because population-based rates are derived differently (i.e., usually from
birth-defect registries). CVS-associated risk for limb deficiencies could be underesti-
mated by these comparisons if follow-up of pregnancies in the exposed cohort is
incomplete. Other epidemiologic issues must also be considered when interpreting
comparisons of crude rates. Unless a formal meta-analysis is performed, these com-
parisons neither account for heterogeneity between studies nor assign individual
“weights” to studies. Comparisons of crude rates also do not adjust for potential con-
founding variables, such as maternal age. Methods of anatomic subclassification also
vary between registries and can differ from methods applied to CVS-exposed cohorts.
In addition, comparing overall rates of limb deficiency in groups exposed to CVS with
groups unexposed to CVS might overlook an association with a specific phenotype,
such as transverse deficiency. 
Published CVS cohort studies of >1,000 CVS procedures include data from 65 CVS
centers (Table 1). These rates include studies that describe affected limbs in sufficient
detail to exclude nontransverse defects. Rates calculated for the smaller cohorts (i.e.,
centers performing <3,500 procedures) are less stable, but the overall rate of nonsyn-
dromic transverse limb deficiency from these centers was 7.4 per 10,000 procedures.
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This crude rate can be compared with rates of transverse deficiencies from Victoria
(Australia) and Boston, Massachusetts (United States), where cases were classified to
resemble the phenotype of CVS-exposed infants with limb deficiencies, including de-
ficiencies of single digits (Table 2). The range of rates for these two populations
(1.5–2.3 per 10,000 births) is representative of rates reported for other populations.
The threefold to fivefold increase in the overall rate for the 65 centers compared with
the rates for Victoria or Boston is statistically significant (chi-square: p<0.001) (17,32 ).
Investigators participating in the International Registry also have combined birth-
defect data from multiple CVS centers, including some of the 65 CVS centers (16,35 ).
An abstract published in 1994 includes information about 138,000 procedures re-
ported to the International Registry. The rate of transverse deficiencies in the reporting
centers was 1.4 per 10,000 procedures, lower than most population-based rates; the
distribution of limb-deficiency subtypes was similar to the results of a study of limb
deficiencies in British Columbia.
The variability in limb-deficiency rates could be related to three possible explana-
tions:
1) Different methods of classification. The method of classification of limb defi-
ciencies for the International Registry resulted in a smaller proportion of
transverse deficiencies (compared with all limb deficiencies) than some popula-
tion-based studies (17,32,36,37 ). The reason for this smaller proportion is that
the definition of “transverse terminal deficiencies” is more restrictive and in-
cludes only defects that extend across the complete width of a limb and
excludes terminal deficiencies of fewer than five digits.











U.S. (NICHD§) (22,23 ) 10 7 9,588  7.3
U.S. (24 )  9 3 4,105  7.3
Netherlands—Rotterdam (25 )  1 3 3,973  7.6
Italy—Sardinia (26 )  1 3 3,082  9.7
U.S.—Beverly Hills, CA (27 )  1 1 3,016  3.3
Germany—Münster (28 )  1 2 2,836  7.1
Italy (GIDEF¶) (29 )  5 3 2,759 10.9
U.S.—Philadelphia, PA (30 )  1 1 2,710  3.7
Denmark (31 )  2 0 2,624  0.0
Australia—Victoria (32 )  2 3 2,071 14.5
Europe (MRC**) (33 ) 31 2 1,609 12.4
U.S.—Evanston, IL (34 )  1 1 1,048  9.5
Total 65 29 39,421  7.4
 *Per 10,000 CVS procedures.
†Excluded were centers (i.e., collaborating hospitals or other health-care facilities) reporting
either ≤1,000 procedures or incomplete information about birth-defect outcomes.
§National Institute of Child Health and Human Development (combined data from two trials
[5,10 ]).
¶Gruppo Italiano Diagnosi Embrio-Fetali.
**Medical Research Council, United Kingdom.
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2) Ascertainment of outcomes. Ascertainment of outcomes may be incomplete in
CVS registries because deliveries can occur at a hospital remote from where the
CVS was performed and might not be reported back to the CVS center. The effect
of this incomplete ascertainment would be to underestimate risk for adverse
outcomes.
3) Differences among centers in the performance of CVS. Investigators have com-
pared rates of miscarriages and rates of limb deficiencies at individual facilities.
This comparison is based on the assumption that the causes of both miscarriage
and limb defects might be related to particular techniques of sampling by indi-
vidual obstetricians. The association between high miscarriage and
limb-deficiency rates in one U.S. CVS center was cited as potential evidence of
the role of surgical inexperience (24).  A cluster of limb deficiencies in another
U.S. teaching hospital (five after 507 CVS procedures) was not associated with
elevated miscarriage rates; chorionic villus sample sizes were larger at this hos-
pital than at another hospital affiliated with the same university that reported no
infants with limb defects (38 ).
Case-Control Studies
Case-control approaches with a minimum of 100 case and 100 control patients
have greater statistical power than cohort studies of 10,000 or fewer births to detect a
fourfold increase in risk for transverse deficiencies (the degree of relative risk sug-
gested by data from the 65 CVS centers) (36 ). Investigators participating in
multicenter birth-defect studies have used this case-control approach both to measure
the strength of the association between CVS and limb deficiency and to determine if a
dose-response (or gradient) effect of risk exists. The latter effect would be indicated by
an increased relative risk for limb deficiency after earlier procedures, suggested in
case reports of CVS-associated limb deficiencies by the high frequency of early
TABLE 2. Comparison of rates* of transverse limb deficiencies in chorionic villus











International Registry† (35 ) 1983–94 20 138,000 1.4 (0.9– 2.2)









Australia–Victoria (32 ) 1990–91 30 129,765 2.3 (1.6–3.3)
U.S.–Boston, MA (17 )¶ 1972–74
1979–90
18 123,489 1.5 (0.9–2.3)
*Per 10,000 procedures, 95% confidence interval.
†Method of classification of limb deficiencies differs from that in the unexposed populations
listed (L. Jackson, personal communication).  
§Method of classification similar to that in the unexposed populations listed.
¶Retabulated from original publication (L. Holmes, personal communication).
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exposures to CVS. Three case-control studies have used infants with limb deficiencies
registered in surveillance systems and control infants with other birth defects to ex-
amine and compare exposure rates to CVS (36,37,39 ). The odds ratios for CVS
exposure (an estimate of the relative risk for limb deficiency after CVS) are summa-
rized in Table 3.
The U.S. Multistate Case-Control Study and the study of the Italian Multicentric
Birth Defects Registry both indicated a significant association between CVS exposure
and subtypes of transverse limb deficiencies (36,37 ). The EUROCAT study did not
analyze risk for transverse limb deficiencies (39 ); the risk for all limb deficiencies
(odds ratio [OR]=1.8, 95% confidence interval [CI]=0.7–5.0) was similar to that meas-
ured in the U.S. Multistate Case-Control Study for all limb deficiencies (OR=1.7, 95%
CI=0.4–6.3) (36 ). Analysis of subtypes in the U.S. study indicated a sixfold increase in
risk for transverse digital deficiencies (36 ). In the U.S. study, no association between
limb deficiencies and amniocentesis was observed.  In the study of the Italian Mul-
ticentric Birth Defects Registry, the association between CVS exposure and transverse
limb deficiencies was stronger (Table 3) (37 ).
GESTATIONAL AGE AT CVS
The lower risk observed in the United States may be related to the later mean ges-
tational age of exposure. Increased risk was associated with decreased gestational
age at the time of exposure (Table 4). The risk for transverse deficiencies was greatest
at ≤9 weeks’ gestation. An analysis of cohort studies regarding the timing of CVS indi-
cated a similar gradient with a relative risk for transverse deficiencies of 6.2 at <10
weeks’ and 2.4 at ≥10 weeks’ gestation (40 ).  Because of reports of high rates of se-
vere limb deficiencies after CVS at 6–7 weeks’ gestation, a WHO-sponsored committee
recommended that CVS be performed at 9–12 weeks after the last menstrual period
(16). 
TABLE 3. Risk for limb deficiencies and subtypes, by selected case-control studies of













Study (36 ) 1.7 (0.4–6.3) 4.7 (0.8–28.4) Digital: 6.4 (1.1–38.6)
EUROCAT (European
Registration of Congenital
Anomalies and Twins) (39 )
1.8 (0.7–5.0) Not subclassified Not subclassified
IMBDR (Italian Multicentric
Birth Defects Registry)** (37 )




§Case definition included only transverse limb deficiencies.
¶Oromandibular-limb hypogenesis (hypoglossia/hypodactyly) (P. Mastroiacovo, personal
communication).
**IPIMC (Indagine Policentrica Italiana sulle Malformazioni Congenite).
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POSSIBLE MECHANISMS OF CVS-ASSOCIATED LIMB
DEFICIENCY
Several biological events have been proposed to explain the occurrence of limb
deficiency after CVS, the variation in severity, and the risk associated with the timing
of the procedure. These mechanisms, which include thromboembolization or fetal
hypoperfusion through hypovolemia or vasoconstriction, are based on the assump-
tion that the defects associated with CVS were caused by some form of vascular
disruption. The limbs and mandible are susceptible to such disruption before 10
weeks’ gestation (17 ); however, isolated transverse limb deficiencies related to fetal
hypoperfusion have been reported at 11 weeks’ gestation (18 ).
The rich vascular supply of chorionic villi can potentially be disrupted by instru-
mentation.  Data from one study of embryoscopic procedures demonstrated fetal
hemorrhagic lesions of the extremities following placental trauma, which produced
subchorionic hematomas (41 ). Placental hemorrhage following CVS could lead to
substantial fetal hypovolemia with subsequent hypoperfusion of the extremities. Be-
cause animal models show that limb deficiencies have been produced by either
vasoconstrictive agents or occlusion of uterine vessels, some researchers have hy-
pothesized that CVS-associated defects might be caused by uteroplacental
insufficiency (42 ). Although the period of highest embryonic susceptibility appears to
be when CVS is performed before 9 weeks’ gestation (i.e., early CVS), these mecha-
nisms also can disrupt limb structures at later gestational ages.
ABSOLUTE RISK FOR LIMB DEFICIENCY
Subtypes of limb deficiencies rarely occur in the population of infants not exposed
to CVS. Thus, even a sixfold increase in risk for such types as digital defects (the find-
ing of the U.S. Multistate Case-Control Study) is comparable to a small absolute risk
(i.e., 3.46 cases per 10,000 CVS procedures [0.03%]) (36 ). The upper 95% confidence
limit for this absolute risk estimate is approximately 0.1%. A range of absolute risk
from 1 per 3,000 to 1 per 1,000 CVS procedures (0.03%–0.10%) for all transverse defi-
ciencies is consistent with the overall increase in risk reported by the 65 centers (Table
TABLE 4. Risk for transverse limb deficiency after chorionic villus sampling (CVS), by






cases OR§ (95% CI)¶
No. of
CVS-exposed
cases OR§ (95% CI)¶
≤9 2 11.3 (1.0–131.6) 8 21.6 (9.0–47.7)
10 4  7.5 (1.5– 36.7) 3 14.3 (3.2–47.2)
≥11 1  5.6 (0.3– 94.7) 0 —**
 *Includes transverse digital deficiencies only (36 ).
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1). In cohort studies that reported the timing of the CVS, the absolute risk for trans-
verse limb deficiencies was 0.20% at ≤9 weeks, 0.10% at 10 weeks, and 0.05% at ≥11
weeks (0.07% at ≥10 weeks of gestation) (40 ).
The absolute risk for CVS-related birth defects is lower than the procedure-related
risk for miscarriage that counselors usually quote to prospective parents (i.e., 0.5% to
1.0%) and also is lower than the risk for Down syndrome at age 35 (0.3%). Data from a
decision analysis study supported the conclusion that, weighing a range of possible
risks associated with prenatal testing, amniocentesis was preferred to CVS (43 ). This
study was published in 1991 and did not consider risk for limb deficiency. Data indi-
cate that publication of the initial case reports of limb deficiency decreased
subsequent utilization of CVS (44,45 ). However, one study demonstrated that pro-
spective parents who were provided with formal genetic counseling, including
information about limb deficiencies and other risks and benefits, chose CVS at a rate
similar to a group of prospective parents who were counseled before published re-
ports of CVS-associated limb deficiencies (44 ).
RECOMMENDATIONS
An analysis of all aspects of CVS and amniocentesis indicates that the occasional
occurrence of CVS-related limb defects is only one of several factors that must be
considered in counseling prospective parents about prenatal testing.  Factors that can
influence prospective parents’ choices about prenatal testing include their risk for
transmitting genetic abnormalities to the fetus and their perception of potential com-
plications and benefits of both CVS and amniocentesis. Prospective parents who are
considering the use of either procedure should be provided with current data for in-
formed decision making.  Individualized counseling should address the following:
Indications for procedures and limitations of prenatal testing
• Counselors should discuss the prospective parents’ degree of risk for transmitting
genetic abnormalities based on factors such as maternal age, race, and family his-
tory.
• Prospective parents should be made aware of both the limitations and usefulness
of either CVS or amniocentesis in detecting abnormalities.
Potential serious complications from CVS and amniocentesis 
• Counselors should discuss the risk for miscarriage attributable to both procedures:
the risk from amniocentesis at 15–18 weeks’ gestation is approximately 0.25%–
0.50% (1/400–1/200), and the miscarriage risk from CVS is approximately
0.5%–1.0% (1/200–1/100). 
• Current data indicate that the overall risk for transverse limb deficiency from CVS is
0.03%–0.10% (1/3,000–1/1,000).  Current data indicate no increase in risk for limb
deficiency after amniocentesis at 15–18 weeks’ gestation.
• The risk and severity of limb deficiency appear to be associated with the timing of
CVS: the risk at <10 weeks’ gestation (0.20%) is higher than the risk from CVS done
at ≥10 weeks’ gestation (0.07%). Most defects associated with CVS at ≥10 weeks’
gestation have been limited to the digits.
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Timing of procedures 
• The timing of obtaining results from either CVS or amniocentesis is relevant be-
cause of the increased risks for maternal morbidity and mortality associated with
terminating pregnancy during the second trimester compared with the first trimes-
ter (13,14).
• Many amniocentesis procedures are now done at 11–14 weeks’ gestation; however,
further controlled studies are necessary to fully assess the safety of early amnio-
centesis.
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